- Home
- FUSB vs APLT Comparison
FUSB vs APLT Comparison
Compare FUSB & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUSB
- APLT
- Stock Information
- Founded
- FUSB 1952
- APLT 2016
- Country
- FUSB United States
- APLT United States
- Employees
- FUSB N/A
- APLT 32
- Industry
- FUSB Major Banks
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- FUSB Finance
- APLT Health Care
- Exchange
- FUSB Nasdaq
- APLT Nasdaq
- Market Cap
- FUSB 69.3M
- APLT 63.6M
- IPO Year
- FUSB N/A
- APLT 2019
- Fundamental
- Price
- FUSB $12.00
- APLT $0.42
- Analyst Decision
- FUSB
- APLT Buy
- Analyst Count
- FUSB 0
- APLT 6
- Target Price
- FUSB N/A
- APLT $6.10
- AVG Volume (30 Days)
- FUSB 3.9K
- APLT 859.9K
- Earning Date
- FUSB 10-23-2025
- APLT 11-06-2025
- Dividend Yield
- FUSB 2.33%
- APLT N/A
- EPS Growth
- FUSB N/A
- APLT N/A
- EPS
- FUSB 0.97
- APLT N/A
- Revenue
- FUSB $36,046,000.00
- APLT $121,000.00
- Revenue This Year
- FUSB N/A
- APLT N/A
- Revenue Next Year
- FUSB N/A
- APLT $5,931.24
- P/E Ratio
- FUSB $12.08
- APLT N/A
- Revenue Growth
- FUSB N/A
- APLT N/A
- 52 Week Low
- FUSB $10.30
- APLT $0.30
- 52 Week High
- FUSB $14.30
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- FUSB 50.32
- APLT 38.92
- Support Level
- FUSB $11.00
- APLT $0.43
- Resistance Level
- FUSB $12.22
- APLT $0.46
- Average True Range (ATR)
- FUSB 0.57
- APLT 0.03
- MACD
- FUSB 0.07
- APLT -0.01
- Stochastic Oscillator
- FUSB 61.98
- APLT 0.35
About FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.